IL158204A0 - Vaccine against the nile fever virus - Google Patents

Vaccine against the nile fever virus

Info

Publication number
IL158204A0
IL158204A0 IL15820402A IL15820402A IL158204A0 IL 158204 A0 IL158204 A0 IL 158204A0 IL 15820402 A IL15820402 A IL 15820402A IL 15820402 A IL15820402 A IL 15820402A IL 158204 A0 IL158204 A0 IL 158204A0
Authority
IL
Israel
Prior art keywords
fever virus
vaccine against
nile fever
nile
vaccine
Prior art date
Application number
IL15820402A
Other languages
English (en)
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of IL158204A0 publication Critical patent/IL158204A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15820402A 2001-04-06 2002-04-05 Vaccine against the nile fever virus IL158204A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Publications (1)

Publication Number Publication Date
IL158204A0 true IL158204A0 (en) 2004-05-12

Family

ID=8862055

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15820402A IL158204A0 (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
IL158204A IL158204A (en) 2001-04-06 2003-10-01 Nile Fever Vaccine
IL185263A IL185263A0 (en) 2001-04-06 2007-08-14 Vaccine against the nile fever virus

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL158204A IL158204A (en) 2001-04-06 2003-10-01 Nile Fever Vaccine
IL185263A IL185263A0 (en) 2001-04-06 2007-08-14 Vaccine against the nile fever virus

Country Status (22)

Country Link
EP (2) EP1377660B1 (pt)
JP (1) JP4426761B2 (pt)
AU (1) AU2002307971B2 (pt)
BE (1) BE2016C021I2 (pt)
BR (1) BRPI0208896B1 (pt)
CA (1) CA2448796C (pt)
CY (2) CY1117676T1 (pt)
DK (1) DK1377660T3 (pt)
ES (2) ES2767413T3 (pt)
FR (2) FR2823222B1 (pt)
HK (2) HK1219412A1 (pt)
HU (2) HU230122B1 (pt)
IL (3) IL158204A0 (pt)
LT (1) LTC1377660I2 (pt)
LU (1) LU93048I2 (pt)
MX (1) MXPA03008998A (pt)
NL (1) NL300806I2 (pt)
PL (2) PL207584B1 (pt)
RU (1) RU2283138C2 (pt)
SI (1) SI1377660T1 (pt)
WO (1) WO2002081621A2 (pt)
ZA (1) ZA200307620B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
MXPA04000680A (es) 2001-07-27 2004-04-05 Wyeth Corp Vacuna para virus west nile.
CA2510229A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
EP1626708B1 (en) 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
HUE037460T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
CA2735164C (en) 2008-08-29 2021-08-31 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
ES2784189T3 (es) 2009-03-27 2020-09-23 Academia Sinica Métodos y composiciones para la inmunización contra virus
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
HU228705B1 (en) * 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
BR0011732B1 (pt) 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
BE2016C021I2 (pt) 2021-03-23
FR2823222B1 (fr) 2004-02-06
DK1377660T3 (en) 2016-03-29
JP4426761B2 (ja) 2010-03-03
BRPI0208896B1 (pt) 2016-06-07
RU2283138C2 (ru) 2006-09-10
IL158204A (en) 2013-03-24
HK1219412A1 (zh) 2017-04-07
MXPA03008998A (es) 2004-10-15
CY1117676T1 (el) 2016-12-14
WO2002081621A3 (fr) 2003-02-20
FR2823222A1 (fr) 2002-10-11
IL185263A0 (en) 2008-01-06
CA2448796C (en) 2012-11-20
SI1377660T1 (sl) 2016-05-31
EP1377660A2 (fr) 2004-01-07
ES2767413T3 (es) 2020-06-17
CY2016018I1 (el) 2016-12-14
LU93048I2 (fr) 2016-06-27
HU230122B1 (hu) 2015-08-28
BR0208896A (pt) 2004-07-20
HK1061868A1 (zh) 2004-10-08
RU2003132455A (ru) 2005-04-27
HUP0401868A2 (hu) 2004-12-28
ZA200307620B (en) 2005-07-27
NL300806I2 (pt) 2016-06-09
FR16C0014I2 (fr) 2016-09-09
LTC1377660I2 (lt) 2017-04-25
AU2002307971B2 (en) 2008-01-17
CY2016018I2 (el) 2016-12-14
HUP0401868A3 (en) 2011-06-28
EP2979705A1 (fr) 2016-02-03
FR16C0014I1 (pt) 2016-05-27
HUS1500047I1 (hu) 2017-03-28
WO2002081621A2 (fr) 2002-10-17
PL210306B1 (pl) 2011-12-30
PL365210A1 (en) 2004-12-27
EP1377660B1 (fr) 2016-01-13
PL207584B1 (pl) 2011-01-31
JP2004531521A (ja) 2004-10-14
ES2566044T3 (es) 2016-04-08
EP2979705B1 (fr) 2019-10-23
CA2448796A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
HUS1500047I1 (hu) Rekombináns vakcina West Nile vírus ellen
IL158066A0 (en) Vaccine composition
HK1067891A1 (en) Influenza vaccine composition
EP1427444A4 (en) WEST NILE VACCINE
GB0130215D0 (en) Vaccine
HUP0402259A3 (en) Vaccines
GB0407935D0 (en) Vaccine
DK1265633T3 (da) Vaccineadjuvans
IL157498A0 (en) Vaccine
EP1423141A4 (en) VACCINE
GB0306611D0 (en) Novel vaccine
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
GB0121171D0 (en) Vaccine
AU2002307971A1 (en) Vaccine against the nile fever virus
EP1395262A4 (en) NUCLEOSIDE-VACCINE-ADJUVANTS
HUP0401182A3 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
GB0105238D0 (en) Vaccines
GB0113552D0 (en) Vaccines
GB0130823D0 (en) Vaccine
GB0115496D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0106589D0 (en) Vaccine
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
PL374051A1 (en) Salmonella vaccine
GB0100288D0 (en) Virus strains